BioGaia AB Class B BIOG B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 120.00
- Day Range
- SEK 118.30–120.40
- 52-Week Range
- SEK 91.20–135.60
- Bid/Ask
- SEK 118.80 / SEK 119.00
- Market Cap
- SEK 11.97 Bil
- Volume/Avg
- 94,227 / 123,826
Key Statistics
- Price/Earnings (Normalized)
- 33.72
- Price/Sales
- 9.23
- Dividend Yield (Trailing)
- 1.21%
- Dividend Yield (Forward)
- 1.58%
- Total Yield
- 1.22%
Company Profile
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions; Asia Pacific, Europe, the Middle East, Africa, and the Americas.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 223
- Website
- https://www.biogaia.se
Comparables
Valuation
|
Metric
|
BIOG B
|
PROB
|
PEXIP
|
|---|---|---|---|
Price/Earnings (Normalized) | 33.72 | 144.25 | 111.44 |
Price/Book Value | 5.89 | 1.84 | 1.79 |
Price/Sales | 9.23 | 4.01 | 2.83 |
Price/Cash Flow | 28.02 | 28.41 | 17.88 |
Price/Earnings
BIOG B
PROB
PEXIP
Financial Strength
|
Metric
|
BIOG B
|
PROB
|
PEXIP
|
|---|---|---|---|
Quick Ratio | 8.65 | 5.31 | 1.82 |
Current Ratio | 9.58 | 6.94 | 1.90 |
Interest Coverage | 529.19 | 5.60 | −30.13 |
Quick Ratio
BIOG B
PROB
PEXIP
Profitability
|
Metric
|
BIOG B
|
PROB
|
PEXIP
|
|---|---|---|---|
Return on Assets (Normalized) | 16.64% | 1.07% | 0.60% |
Return on Equity (Normalized) | 18.93% | 1.18% | 0.77% |
Return on Invested Capital (Normalized) | 17.34% | 0.74% | −0.02% |
Return on Assets
BIOG B
PROB
PEXIP
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Kbrxlxnb | Phtftxz | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Qjwxhjjcpj | Qrpp | $70.0 Bil | |
HLN
| Haleon PLC ADR | Wrflsvkn | Fdctf | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Zlrhtvrqt | Bybn | $14.3 Bil | |
VTRS
| Viatris Inc | Rwlxxbxxt | Dfkdz | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zltpphr | Znk | $12.0 Bil | |
CTLT
| Catalent Inc | Ylmnkdsc | Nxybnh | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Pkxkryjz | Dpwr | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Nhqtzdll | Jlpb | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Zfvvqcn | Wfnmdh | $3.4 Bil |